Charles River Laboratories International (NYSE:CRL) Price Target Cut to $190.00 by Analysts at The Goldman Sachs Group

Charles River Laboratories International (NYSE:CRL) had its target price decreased by equities research analysts at The Goldman Sachs Group from $220.00 to $190.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 14.51% from the company’s current price.

Several other equities analysts also recently commented on the company. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. UBS Group restated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Finally, CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $204.38.

Charles River Laboratories International Stock Performance

NYSE:CRL traded down $2.30 during midday trading on Thursday, reaching $165.92. The stock had a trading volume of 113,096 shares, compared to its average volume of 976,373. The stock has a market capitalization of $8.49 billion, a P/E ratio of 20.70, a PEG ratio of 5.97 and a beta of 1.38. Charles River Laboratories International has a 1-year low of $160.85 and a 1-year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm’s fifty day simple moving average is $187.81 and its 200-day simple moving average is $197.72.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the prior year, the company earned $2.72 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current fiscal year.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently made changes to their positions in CRL. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after acquiring an additional 509,163 shares during the period. Earnest Partners LLC raised its holdings in Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after acquiring an additional 110,725 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Charles River Laboratories International by 73.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock worth $49,561,000 after purchasing an additional 101,732 shares in the last quarter. Finally, Mizuho Securities USA LLC increased its position in shares of Charles River Laboratories International by 2,336.4% in the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after purchasing an additional 92,895 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).